4.7 Article

Trends in the Management and Outcomes of Acute Pulmonary Embolism Analysis From the RIETE Registry

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.10.060

关键词

heparin; length of stay; outcomes; prognosis; surgical embolectomy; survival; thrombolysis

资金

  1. Sanofi
  2. ROVI
  3. Leo Pharma
  4. Boehringer Ingelheim
  5. Bayer HealthCare
  6. Bayer HealthCare Pharmaceuticals, Inc.
  7. Portola, Inc.
  8. Pfizer, Inc.
  9. Bristol-Myers Squibb
  10. Bayer

向作者/读者索取更多资源

BACKGROUND Despite advances in hospital management in recent years, it is not clear whether mortality after acute pulmonary embolism (PE) has decreased over time. OBJECTIVES This study describes the trends in the management and outcomes of acute symptomatic PE. METHODS We identified adults with acute PE enrolled in the registry between 2001 and 2013. We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies. Using multivariable regression, we examined temporal trends in risk-adjusted rates of all-cause and PE-related death to 30 days after diagnosis. RESULTS Among 23,858 patients with PE, mean length of stay decreased from 13.6 to 9.3 days over time (32% relative reduction, p < 0.001). For initial treatment, use of low-molecular-weight heparin increased from 77% to 84%, whereas the use of unfractionated heparin decreased from 22% to 8.4% (p < 0.001 for trend for all comparisons). Thrombolytic therapy use increased from 0.7% to 1.0% (p = 0.07 for trend) and surgical embolectomy use doubled from 0.3% to 0.6% (p < 0.01 for trend). Risk-adjusted rates of all-cause mortality decreased from 6.6% in the first period (2001 to 2005) to 4.9% in the last period (2010 to 2013) (p = 0.02 for trend). Rates of PE-related mortality decreased over time, with a risk-adjusted rate of 3.3% in 2001 to 2005 and 1.8% in 2010 to 2013 (p < 0.01 for trend). CONCLUSIONS In a large international registry of patients with PE, improvements in length of stay and changes in the initial treatment were accompanied by a reduction in short-term all-cause and PE-specific mortality. (C) 2016 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据